Method AI Secures $20M to Revolutionize Robotic Surgery
In a bold leap forward for surgical precision, Method AI, a Boston-based medtech innovator, has clinched $20 million in Series A funding to enhance its cutting-edge platform for robotic oncology surgery.
Spun out from the Cleveland Clinic in 2021, Method AI is tackling one of the toughest challenges in cancer treatment: visualizing tumors hidden beneath organ surfaces, a blind spot for current surgical camera systems.
Their solution? A groundbreaking platform that delivers continuous 3D ultrasound imaging, creating real-time subsurface maps to guide surgeons with AI-driven precision.
Led by CEO Doug Teany, a former Corindus COO, Method AI aims to address a critical issue in robotic surgery, where up to 40% of oncology procedures fail to fully remove tumors due to poor visualization.
This can lead to cancer recurrence, complications, or loss of organ function. By integrating 3D ultrasound with machine learning, Method AI’s platform offers surgeons a dynamic, subsurface view of anatomy, paired with real-time guidance akin to an AI-generated surgical GPS.
This could drastically improve patient outcomes, particularly in complex procedures like bladder tumor removals, where robotic surgery already reduces readmissions by 52% and blood clots by 77%, according to a 2022 University College London trial.
The funding round, led by an unnamed private family office, saw participation from Cleveland Clinic and JobsOhio Growth Capital Fund. With this capital, Method AI plans to accelerate development, refine its surgical navigation platform, and push toward commercialization.
The company envisions reducing healthcare costs by over $1 billion annually by improving cancer-free survival rates. As the global robotic surgical systems market surges toward a projected $9.2 billion by 2034, Method AI’s fusion of AI and imaging tech positions it as a trailblazer in a rapidly evolving field.
FAQ
What does Method AI’s platform do?
Method AI’s platform uses continuous 3D ultrasound imaging and AI to create real-time subsurface maps, helping surgeons visualize and remove tumors during robotic oncology procedures.
How will the $20M funding be used?
The funds will support further development of Method AI’s surgical navigation platform, aiming to enhance its capabilities and bring it to market to improve cancer surgery outcomes.
Image Credit: Pixabay
